Novo Nordisk has announced the cessation of the Evoke trials, looking at whether GLP-1 drugs could help tackle Alzheimer’s. Image credit: NurPhoto/Getty Images
Pharmaceutical giant Novo Nordisk recently conducted a large-scale study investigating whether weight-loss drug semaglutide could slow Alzheimer’s progression.